Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK

Nav

General Info

Geography

Belgium (BEL)

Italy (ITA)

Sweden (SWE)

United Kingdom (GBR)

Coverage type

Country

Time period covered

01/2009 - 12/2010

Data type

Scientific literature

Keywords

HIV and AIDS, Health care costs, Health care expenditures

Citation

Authors

Moeremans K, Hemmett L, Hjelmgren J, Allegri G, Smets E

Journal

Pharmacoeconomics

Volume

28 Suppl 1

Pages

147-67

Publication year

2010

Suggested citation

Moeremans K, Hemmett L, Hjelmgren J, Allegri G, Smets E. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK. Pharmacoeconomics. 2010; 28 Suppl 1: 147-67.

DOI

10.2165/11587500-000000000-00000

PMID

21182349

GHDx Entry last modified on: Apr 10, 2023

Header sites

Search form

Main menu

Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK

Nav